The presence of glass can lead to serious adverse events, including inflammation of a vein and blockage of blood vessels or life-threatening blood clots.
Hospira is recalling several products because glass particulates were found during product inspection. The presence of glass can lead to serious adverse events, including inflammation of a vein, granuloma, and blockage of blood vessels or life-threatening blood clots.
This recall impacts:
To date, Hospira has not received reports of any adverse events associated with these products.
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More